Smart Artificial Intelligence for Trial Linking enters active
ClinicalTrials.gov lists Smart Artificial Intelligence for Trial Linking as active but not recruiting, with baseline matching as the main outcome and no results posted yet.
ClinicalTrials.gov lists Smart Artificial Intelligence for Trial Linking as ACTIVE_NOT_RECRUITING, and that is the latest visible status in the record. The study is tied to the European Institute of Oncology and has no posted results yet, so this is a registry update rather than a finding about whether the approach works.
For a general reader, the point is straightforward: the study is about comparing standard matching with automatic matching when patients are linked to phase I clinical trials. In other words, it is trying to see whether an automated system can line up trial options with patients in a consistent way at the moment of matching.
"The primary unit of analysis is the patient-trial pair." — source: ClinicalTrials.gov registry observation for Smart Artificial Intelligence for Trial Linking
What the study is measuring
The study is observational and non-interventional, which means it records what happens without assigning a treatment. Its primary outcome is the concordance between standard and automatic matching, measured at baseline.
That baseline detail matters because the record says all data will be collected and reported at the time of matching. It also says multiple trial-level observations may come from the same patient, so those patient-trial pairs will be treated as clustered within patient rather than independent observations.
Why it matters now
The record also gives a time anchor for its planned completion: the primary completion date is 2027-01-01 and the primary completion type is ESTIMATED. That keeps the study in the realm of ongoing registry activity, not a finished result.
Because has_results is false, there is no outcome to interpret yet. The safest reading is that this entry shows a testing phase for a matching process, not proof that the process is better than standard practice.
Where this fits in Cancer Breakthroughs
This registry observation sits within the special event Cancer Breakthroughs, but it should be read on its own terms. It connects to a larger cancer-trial landscape without implying that every listed study answers the same question.
For readers following cancer research updates, the practical takeaway is that trial access is itself becoming a subject of study. Better matching could help make trial searches less dependent on chance, but the registry entry does not claim that result; it only shows the study design and status.